Do ACE and AGT gene variants alter RAAS tone and increase hypertension and CKD risk?

Genetic variations in the Angiotensin-Converting Enzyme (ACE) and Angiotensinogen (AGT) genes are well-established modifiers of the renin–angiotensin–aldosterone system (RAAS). These variants influence the baseline "tone" or activity level of the system, which directly impacts vascular resistance and renal health.

Clinical and effectiveness evidence

Large-scale meta-analyses and cohort studies have consistently linked specific variants in the ACE and AGT genes to increased risks of hypertension and chronic kidney disease (CKD):

• Hypertension Risk: The ACE rs4343 variant (linked to the classic I/D polymorphism) shows a significant association with essential hypertension. In some populations, the AA genotype has been associated with a nearly 3-fold increase in hypertension risk in males (OR = 2.96). Similarly, the AGT rs699 (M235T) variant is a recognized contributor to hypertension, with the T allele increasing susceptibility across diverse ethnic groups.
• Chronic Kidney Disease: The presence of high-activity RAAS variants correlates with accelerated renal decline. The ACE GG genotype (associated with the "D" allele) is linked to a higher incidence of diabetic nephropathy and end-stage renal disease (ESRD). For AGT, the rs699 T allele is associated with an increased risk of CKD, with meta-analyses showing odds ratios for renal progression typically ranging from 1.3 to 1.5.

Mechanistic explanations

The association between these genes and disease risk is driven by direct changes in protein concentration and enzymatic activity:

• ACE Activity: The ACE rs4343 G allele (tagging the Deletion variant) accounts for approximately 50% of the variance in serum ACE levels. Individuals with the GG (DD) genotype exhibit roughly 2-fold higher plasma ACE levels than those with the AA (II) genotype, leading to increased conversion of Angiotensin I to the potent vasoconstrictor Angiotensin II.
• Substrate Availability: The AGT rs699 T allele leads to higher circulating levels of angiotensinogen, the rate-limiting substrate for the entire RAAS cascade. This increases the total capacity for Angiotensin II production.
• Renal Impact: Chronic RAAS overactivity promotes intraglomerular hypertension, increases proteinuria, and activates pro-fibrotic pathways (such as TGF-beta), which collectively drive podocyte damage and renal fibrosis.

Bottom line

Variants in the ACE and AGT genes significantly influence systemic RAAS tone, with specific genotypes (such as ACE DD/GG and AGT 235T) acting as functional modifiers that increase the risk of hypertension and the progression of chronic kidney disease.